Thomas Gravelyn, MD
Pulmonary Disease · Ypsilanti, MINPI 1760442636
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $82,090 of the $103,523 with a category attached, or 79.3%. Sunovion Pharmaceuticals Inc. accounts for 83.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $96,688 and has fallen 99.9% since, to $83 in 2023. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 144 payments — averaging $718.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$86K
- Boehringer Ingelheim$17K
- 3b Medical, Inc.$83
- Harmony Biosciences LLC$14
What the payments were for
- Speaking & faculty fees$82,09079%
- Travel & lodging$19,24419%
- Food & beverage$2,1892%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 120 | $86,208 |
| Boehringer Ingelheim | 22 | $17,218 |
| 3b Medical, Inc. | 1 | $83 |
| Harmony Biosciences LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$84,572
How this compares
$103,523 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 56 | $54,509 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 59 | $54,006 |
| Spiriva RespimatTiotropium Bromide | 44 | $40,094 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $18,479 |
| Spiriva HandihalerTiotropium Bromide | 16 | $17,129 |
| Tiotropium Bromide | 18 | $11,882 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 28 | $11,729 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $10,335 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $8,656 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $8,303 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $4,488 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $3,697 |
| Pulmicort FlexhalerBudesonide | 11 | $3,610 |
| Modafinil | 58 | $2,683 |
| Roflumilast | 18 | $2,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $17,218 | $94,603100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Ypsilanti
- Arwa Mohamed HosniYpsilanti$15K
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.